1. Improving Decision-Making Processes in Health: Is It Time for (Disease-Specific) Reference Models?

   • Hossein Haji Ali Afzali
   • Laura Bojke
   • Jonathan Karnon

   Editorial 20 August 2019 Pages: 1 - 4

2. Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

   • Caridad Pontes
   • Corinne Zara
   • Brian Godman

   Current Opinion 07 November 2019 Pages: 5 - 16

3. Determining the Baseline Strategy in a Cost-Effectiveness Analysis with Treatment Sequences

   • Marta Giulia Viola
   • Alexander Diamantopoulos

   Practical Application 20 September 2019 Pages: 17 - 29

   

4. Using the Threshold Technique to Elicit Patient Preferences: An Introduction to the Method and an Overview of Existing Empirical Applications

   • Brett Hauber
   • Joshua Coulter

   Review Article 20 September 2019 Pages: 31 - 46

   

5. Price Models for Multi-indication Drugs: A Systematic Review

   • Carlos Campillo-Artero
   • Jaume Puig-Junoy
   • Marta Trapero-Bertran

   Systematic Review 16 September 2019 Pages: 47 - 56

   

6. Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System

   • Ângela J. Ben
   • Jeruza L. Neyeloff
   • Cristina R. Neumann

   Original Research Article Open access 01 November 2019 Pages: 57 - 68

   

7. A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance

   • David J. Mott
   • Grace Hampson
   • Michael M. Hopkins

   Original Research Article Open access 20 September 2019 Pages: 69 - 79

   

8. Why Do Informal Sector Workers Not Pay the Premium Regularly? Evidence from the National Health Insurance System in Indonesia

   • Teguh Dartanto
   • Alin Halimatussadiah
   • Rooswanti Soeharno

   Original Research Article 18 September 2019 Pages: 81 - 96

   

9. Estimating Attribute-Specific Willingness-to-Pay Values from a Health Care Contingent Valuation Study: A Best–Worst Choice Approach

   • Ivan Sever
   • Miroslav Verbič
   • Eva Klaric Sever

   Original Research Article 28 September 2019 Pages: 97 - 107

   

10. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany

    • Afschin Gandjour
    • Dennis A. Ostwald

    Original Research Article 07 November 2019 Pages: 109 - 125

    

11. Forecasting Ontario Oncology Drug Expenditures: A Hybrid Approach to Improving Accuracy

    • Paula M. Murray
    • Yusuf A. Shalaby
    • Jessica Arias

    Original Research Article 14 November 2019 Pages: 127 - 137

    

12. Comment on: “Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018–2040”

    • Muhammad Radzi Abu Hassan
    • Huan-Keat Chan

    Letter to the Editor 19 December 2019 Pages: 139 - 140

13. Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

    • Renée Else Michels
    • Maria De Francesco
    • Marieke Krol

    Correction Open access 14 January 2020 Pages: 141 - 141